Apellis Pharmaceuticals And Sobi Announce Positive One-Year Results From Phase 2 NOBLE Study Of Pegcetacoplan For Post-Transplant Recurrence Of C3 Glomerulopathy (C3G) And IC-MPGN
Portfolio Pulse from Benzinga Newsdesk
Apellis Pharmaceuticals and Sobi announced positive one-year results from the Phase 2 NOBLE study of Pegcetacoplan for post-transplant recurrence of C3 Glomerulopathy (C3G) and IC-MPGN. The study showed sustained reduction in disease activity and significant clearance of C3c deposits. These results were presented at the European Renal Association Congress.
May 24, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Apellis Pharmaceuticals announced positive one-year results from the Phase 2 NOBLE study of Pegcetacoplan, showing sustained reduction in disease activity and significant clearance of C3c deposits in patients with C3G and IC-MPGN.
The positive results from the Phase 2 NOBLE study indicate that Pegcetacoplan is effective in reducing disease activity and clearing C3c deposits in patients with C3G and IC-MPGN. This is likely to boost investor confidence and positively impact the stock price of Apellis Pharmaceuticals in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100